Skip to content

Investor Relations / Publications / Amarin Supported Peer Reviewed Articles EPA Research, Case Studies, Overviews

Amarin Supported Peer Reviewed Articles EPA Research, Case Studies, Overviews

To search publications using the available search words, please click here:

S.C.R. Sherratt, R.A. Juliano and R.P. Mason, Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro, BBA - Biomembranes(2020)

Lakshmanan S, Shekar C, Kinninger A, Dahal S, Onuegbu A, Cai AN, Hamal S, Birudaraju D, Roy SK, Nelson JR, Budoff MJ, Bhatt DL. Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography. Cardiovasc Res. 2020;116(3):479-82.

Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of new heart failure diagnosis: A real-world analysis of high-risk statin-treated patients. Vasc Health Risk Manag. 2019;15:533-538.

Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk By Statin Use In U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014. Diabetes Care. 2019. [Epub ahead of print]

Gitt AK. Prevalence Of Hypertriglyceridaemia In Statin Treated Very High-Risk Patients Who Might Benefit From Treatment With Icosapent Ethyl For Secondary Prevention In Clinical Practice–Results Of DYSIS. EMJ Cardiol. 2019;7:61-62.

Toth PP, Philip S, Hull M, Granowitz C. Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patientsMayo Clin Proc. 2019;94(9):1670-1680.

Toth PP, Philip S, Hull M, Granowitz C. Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysisClin Cardiol. 2019;1–6.

Case BC, Bress A, Kolm P, Philip S, Herrick J, Granowitz C, Toth P, Fan W, Wong N, Hull M, Weintraub S. The Economic Burden of Hypertriglyceridemia Among US Adults With Diabetes or Atherosclerotic Cardiovascular Disease on Statin TherapyJ Clin Lipidol. 2019; epub ahead of print.

Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. Generalizability of the REDUCE-IT trial in patients with stable coronary artery diseaseJ Am Coll Cardiol. 2019;73:1362-1364.

Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high vs. normal triglycerides despite statin-controlled LDL cholesterolDiabetes Obes Metab. 2019;21:366-371.

Nichols GA, Philip S, Reynolds K, Granowitz CB, O’Keeffe-Rosetti M, Fazio S. Comparison of medical care utilization and costs among patients with statin-controlled LDL cholesterol with versus without hypertriglyceridemia. Am J Cardiol. 2018. Doi: 10.1016/j.amjcard.2018.06.029.

Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.

Mason RP, Dawoud H, Jacob RF, Sherratt SCR, Malinski T. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statinBiomed Pharmacother. 2018;103:1231-7.

Borow KM, Mason RP, Vijayaraghavan K. Eicosapentaenoic acid as a potential therapeutic approach to reduce cardiovascular risk in patients with end-stage renal disease on hemodialysis: a review. Cardiorenal Med. 2018;8:18-30.

Mason RP, Sherratt SCR. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochem Biophys Res Comm. 2017;483:425-429.

Mason RP, Jacob RF, Shrivastava S, Sherratt SC, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858:3131-3140.

Crandell JR. Switching from EPA + DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl) in a statin-treated patient with persistent dyslipidemia and high cardiovascular risk: a case study. Clin Med Insights Cardiol. 2016;10:123-128.

Philip S, Chowdhury S, Nelson JR, Benjamin Everett P, Hulme-Lowe CK, Schmier JK. A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. J Med Econ. 2016;19:1003-10010.

Mason RP, Sherratt SCR, Jacob RF. Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. J Cardiovasc Pharmacol. 2016;68:33-40.

Amarin Corporation